title: Immune response to combination therapy for non-Hodgkin lymphomas.
abstract: A parametric model of tumor response to combination therapy in the presence of an immune system is described. Synergistic mechanisms which induce tumor regression are simulated with a coupled set of equations. The simulations are first compared to tumor history data obtained with a SCID mouse model to determine key parameters; predictions are then made for an immune-competent animal. The minimum immune cell birth rate relative to malignant B-cell birth rate necessary to induce tumor regression is determined, and optimization of drug combinations in the presence of an immune response is explored. The delayed effect of an immune response relative to drug scheduling is examined, and a mechanism for disease transformation in heterogeneous tumors is proposed.
authors: President, Back Bay Biosciences LLC, Boston, Massachusetts, United States of America.
authors: Robert F
authors: RF
authors: Weiss
authors: Merlin G
authors: MG
authors: Miller
authors: John F
authors: JF
authors: Cronin
mesh_terms: D000818:Animals; D018951:Antigens, CD20 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D049109:Cell Proliferation / Q000187:drug effects; D018450:Disease Progression; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D051379:Mice; D016513:Mice, SCID; D008954:Models, Biological; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D013997:Time Factors
chemical_list: D018951:Antigens, CD20; D000970:Antineoplastic Agents; D019253:Proto-Oncogene Proteins c-bcl-2